Establishing Pediatric CNS Pharmacodynamic Measures as Tools to Enable Psychiatric Indications in Adolescents
Past Federal grant forecast Posted
- Opportunity number
- PAR-26-049
- Agency
-
National Institutes of Health
Department of Health and Human Services
- Applications expected due
- Award size
- Not on record
Opportunity facts
- Expected posting
- Assistance listings
- Funding instrument
- Cooperative Agreement
- Category
-
- Health
- Eligible applicants
-
- Public or Indian Housing Auth.
- Independent School Districts
- City/Township Governments
- Small Businesses
- Non-501(c)(3) Nonprofits
- Higher Education Inst. (Public)
- Higher Education Inst. (Private)
- Special District Governments
- State Governments
- Tribal Organizations (Not Federally Recognized)
- 501(c)(3) Nonprofits
- Other
- County Governments
- For Profit Organizations
- Tribal Governments (Federally Recognized)
- Points of contact
-
- Margaret C. Grabb mgrabb@mail.nih.gov (301) 443-3563
Opportunity details come from Grants.gov. Updated .
About this opportunity
The National Institute of Mental Health is forecasting a cooperative agreement opportunity to support research developing central nervous system pharmacodynamic measures to enable psychiatric indications in adolescents, with a formal NOFO anticipated but applications not currently being solicited; researchers are encouraged to develop meaningful collaborations now in preparation for future application.
NIMH seeks research establishing dosing strategies and tools for testing new psychiatric medications in children and adolescents with serious mental illnesses. The work will develop and refine CNS tools and models demonstrating how medications affect the brain in young people, including functional brain imaging methods such as EEG or fMRI, digital health measures, and cognitive assessments. Applications should explore how dosing impacts drug exposure (pharmacokinetics) and related CNS functional effects (pharmacodynamics), with the goal of improving safety and effectiveness of pediatric clinical trials by establishing pediatric pharmacodynamic measures, associating pharmacodynamic data with pharmacokinetic data, and creating associated models.
Eligible applicants include higher education institutions (public and private), nonprofit organizations (501(c)(3) and non-501(c)(3)), small businesses, for-profit organizations, state and local governments, tribal governments (federally recognized and not), Indian/Native American tribal governments, eligible federal agencies, U.S. territories or possessions, and regional and non-domestic entities.
The funding falls under CFDA 93.242 (Mental Health Research Grants). NIMH typically supports projects for up to five years, with review by scientific peer review panels and the National Advisory Mental Health Council. Researchers with expertise in pediatric psychiatry, neuroimaging, pediatric clinical pharmacology, clinical trials, or related fields are encouraged to consider applying once the NOFO is released.
Forecast synopsis
The National Institute of Mental Health (NIMH) seeks research that helps determine the best dosing strategies when testing new psychiatric medications in children and adolescents with serious mental illnesses.This NOFO will focus on developing and refining central nervous system (CNS) tools and models that can show how medications affect the brain in young people. These tools might include functional brain imaging methods like EEG or fMRI, as well as digital health measures or cognitive assessments. Studies are encouraged that explore how dosing impacts drug exposure (pharmacokinetics) and related CNS functional effects (pharmacodynamics). The overall goal is to improve the safety and effectiveness of pediatric clinical trials by developing pediatric pharmacodynamic measures, to associate pharmacodynamic data with pharmacokinetic data, and to establish associated models. Applications are not being solicited at this time. Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. Researchers with expertise in pediatric psychiatry, neuroimaging, pediatric clinical pharmacology, clinical trials, or related fields are encouraged to consider applying to the new NOFO.
Eligibility
Other Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U.S. Territory or Possession;Regional Organizations;Non-domestic (non-U.S.) Entities (Foreign Institutions).
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar grant opportunities
- Ask GovTribe AI about this opportunity